Naxitamab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Naxitamab (Hu3F8) 是一种人源化单克隆抗体，靶向二氮冈糖苷 GD2 (hu3F8)。Naxitamab 可用于神经母细胞瘤、骨肉瘤和其他 GD2 阳性癌症的研究。

Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers.

Naxitamab (Hu3F8; 72 h) has cytotoxicity against neuroblastoma cell line LAN-1 with an EC50 value of 5.1 μg/mL.Naxitamab (0.1-1 μg/mL; 4 h; peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN)) has antibody-dependent cell-mediated cytotoxic effects (ADCC).

Naxitamab (Hu3F8; 100 mg/kg; i.v.; twice a week, for 4 weeks; athymic nude mice with LAN-1 xenografts) inhibits tumor growth in neuroblastoma xenografts.Animal Model:Female athymic nude mice with LAN-1 xenografts Dosage:100 mg/kg Administration:Intravenous injection; twice a week, for 4 weeks Result:Inhibited tumor growth and prolonged the survival time.

——

Others

Other Targets

Others

——

——

1879925-92-4

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years